Yvonne Y. Li

机构：Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center · ORCID：0000-0002-1741-1995

发表论文 594 篇 · 总被引 1497 次 · h-index 20

代表论文

• A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM , BRCA1 , BRCA2 , PALB2 , and CHEK2 (2026 · Clinical Cancer Research · 被引 2)
• Figure S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer (2026)
• Supplementary Figure S1 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2 (2026)
• Supplementary Figure S3 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2 (2026)
• Supplementary Figure S6 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2 (2026)
• Supplementary Table S1 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2 (2026)